Publications

Zavoriti and Miossec explored the impact of tofacitinib on inflammation and coagulation in RA. Tofacitinib reduced synovial and vascular inflammation by inhibiting IFNɣ, IL-17A, and IL-6 production but failed to prevent the prothrombotic effects of inflammatory cytokines on endothelial cells. These findings suggest that while tofacitinib reduces inflammation, it does not mitigate associated thrombotic risk.

The study used cocultures of human peripheral blood mononuclear cells with RA synoviocytes or endothelial cells to simulate cytokine production in RA. The publication aimed to evaluate the effect of tofacitinib on endothelial activation and coagulation under inflammatory conditions, explaining its link to increased cardiovascular risk.